Mark E Zafereo1, Li Xu1, Kristina R Dahlstrom1, Carlo A Viamonte1, Adel K El-Naggar2, Qingyi Wei3, Guojun Li4, Erich M Sturgis5. 1. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. 2. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. 3. Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, United States. 4. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. 5. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Electronic address: esturgis@mdanderson.org.
Abstract
OBJECTIVE: Human papillomavirus (HPV) is a causal and prognostic factor for oropharyngeal cancer, but its role in squamous cell carcinoma of the oral cavity (SCCOC) is unclear. We sought to clarify HPV's role in SCCOC. MATERIALS AND METHODS: Patients with newly diagnosed SCCOC (N=460) were prospectively recruited, treated, and followed at one institution. p16/HPV status was determined by p16 immunohistochemistry (IHC) (N=210), PCR-based HPV 16/18 E6/7 DNA testing (N=403), and/or HPV in situ hybridization (ISH) (N=178). Kaplan-Meier curves and log-rank tests were used to compare survival by p16/HPV status. RESULTS: p16 expression was detected in 30% of tumors (62/210) and HPV 16/18 E6/7 DNA in 28% (114/403), although correlation between these two assays was poor (r=-0.01). Patients with p16-positive tumors were more likely to be younger and have primary tumors of the oral tongue. Only 4% of tumors (7/171) were positive for HPV by ISH. Comparisons of patients with p16-positive and p16-negative tumors, patients with HPV-positive and HPV-negative tumors by PCR, and patients with HPV-positive and HPV-negative tumors by ISH showed no significant differences in disease-specific or disease-free survival by p16/HPV status. When we applied a more stringent definition of HPV positivity based on a combination of assay results, only 10 of 166 tumors were HPV positive, and there were no significant differences in demographic, exposure, clinical, or survival characteristics between these patients and the 156 HPV-negative patients. CONCLUSIONS: Very few patients with SCCOC have HPV-driven tumors. SCCOC that overexpresses p16 may be a unique subset deserving of further study.
OBJECTIVE:Human papillomavirus (HPV) is a causal and prognostic factor for oropharyngeal cancer, but its role in squamous cell carcinoma of the oral cavity (SCCOC) is unclear. We sought to clarify HPV's role in SCCOC. MATERIALS AND METHODS:Patients with newly diagnosed SCCOC (N=460) were prospectively recruited, treated, and followed at one institution. p16/HPV status was determined by p16 immunohistochemistry (IHC) (N=210), PCR-based HPV 16/18 E6/7 DNA testing (N=403), and/or HPV in situ hybridization (ISH) (N=178). Kaplan-Meier curves and log-rank tests were used to compare survival by p16/HPV status. RESULTS:p16 expression was detected in 30% of tumors (62/210) and HPV 16/18 E6/7 DNA in 28% (114/403), although correlation between these two assays was poor (r=-0.01). Patients with p16-positive tumors were more likely to be younger and have primary tumors of the oral tongue. Only 4% of tumors (7/171) were positive for HPV by ISH. Comparisons of patients with p16-positive and p16-negative tumors, patients with HPV-positive and HPV-negative tumors by PCR, and patients with HPV-positive and HPV-negative tumors by ISH showed no significant differences in disease-specific or disease-free survival by p16/HPV status. When we applied a more stringent definition of HPV positivity based on a combination of assay results, only 10 of 166 tumors were HPV positive, and there were no significant differences in demographic, exposure, clinical, or survival characteristics between these patients and the 156 HPV-negative patients. CONCLUSIONS: Very few patients with SCCOC have HPV-driven tumors. SCCOC that overexpresses p16 may be a unique subset deserving of further study.
Authors: Julia E Heck; Julien Berthiller; Salvatore Vaccarella; Deborah M Winn; Elaine M Smith; Oxana Shan'gina; Stephen M Schwartz; Mark P Purdue; Agnieszka Pilarska; Jose Eluf-Neto; Ana Menezes; Michael D McClean; Elena Matos; Sergio Koifman; Karl T Kelsey; Rolando Herrero; Richard B Hayes; Silvia Franceschi; Victor Wünsch-Filho; Leticia Fernández; Alexander W Daudt; Maria Paula Curado; Chu Chen; Xavier Castellsagué; Gilles Ferro; Paul Brennan; Paolo Boffetta; Mia Hashibe Journal: Int J Epidemiol Date: 2009-12-18 Impact factor: 7.196
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Kristina R Dahlstrom; Jarrod A Little; Mark E Zafereo; Margaret Lung; Qingyi Wei; Erich M Sturgis Journal: Head Neck Date: 2008-01 Impact factor: 3.147
Authors: Morgan A Gingerich; Joshua D Smith; Nicole L Michmerhuizen; Megan Ludwig; Samantha Devenport; Chloe Matovina; Chad Brenner; Steven B Chinn Journal: Head Neck Date: 2018-02-10 Impact factor: 3.147
Authors: Ye Tao; Erich M Sturgis; Zhigang Huang; Yan Sun; Kristina R Dahlstrom; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2018-05-02 Impact factor: 7.396
Authors: Anshu Khanna; Eric M Sturgis; Kristina R Dahlstrom; Li Xu; Qingyi Wei; Guojun Li; Neil D Gross Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166
Authors: Angela L Mazul; Nidia Rodriguez-Ormaza; James M Taylor; Dipan D Desai; Paul Brennan; Devasena Anantharaman; Tarik Gheit; Massimo Tommasino; Behnoush Abedi-Ardekani; Andrew F Olshan; Jose P Zevallos Journal: Oral Oncol Date: 2016-09-06 Impact factor: 5.337
Authors: Kristina R Dahlstrom; Karen S Anderson; Matthew S Field; Diego Chowell; Jing Ning; Nan Li; Qingyi Wei; Guojun Li; Erich M Sturgis Journal: Cancer Date: 2017-09-12 Impact factor: 6.860
Authors: Sophie Deneuve; Joanne Guerlain; Agnès Dupret-Bories; Claire Majoufre; Pierre Philouze; Philippe Ceruse; Marion Perreard; Nicolas Sigaud; Béatrix Barry; Pierre Ransy; Philippe Schultz; Olivier Malard; Sylvain Morinière; Anne Chatellier; Erwan De Monès; Mireille Folia; François Virard; Béatrice Fervers Journal: Eur Arch Otorhinolaryngol Date: 2021-04-20 Impact factor: 2.503